Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study on the Effects of Obexelimab for Patients with Relapsing Multiple Sclerosis

    Not recruiting

    2 1
    Investigated Drugs:
    Austria Belgium Croatia Czechia Denmark Finland +4
  • Study on Testosterone Undecanoate for Neuroprotection and Myelin Repair in Patients with Relapsing Remitting Multiple Sclerosis

    Not recruiting

    2 1 1
    Investigated Drugs:
    France
  • Study on the Safety and Effectiveness of Peginterferon Beta-1a for Children and Teens with Relapsing-Remitting Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Bulgaria Croatia Czechia Hungary Slovakia
  • Study on the Safety and Effectiveness of Ocrelizumab vs. Fingolimod for Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

    Not recruiting

    3 1 1
    Austria Belgium Bulgaria Croatia Denmark Estonia +11
  • Study on the Effects of a Higher Dose of Ocrelizumab for Adults with Relapsing Multiple Sclerosis

    Not recruiting

    3 1 1
    Belgium Denmark France Germany Greece Hungary +4
  • Study comparing stem cell transplantation versus alemtuzumab, cladribine or ocrelizumab in patients with aggressive relapsing-remitting multiple sclerosis

    Not recruiting

    3 1 1 1
    Denmark The Netherlands Norway Sweden
  • Study on the Safety and Effects of Ocrelizumab for Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

    Not recruiting

    2 1 1 1
    Italy Poland
  • Study on the Effectiveness and Safety of Ocrelizumab, Methylprednisolone, and Diphenhydramine Hydrochloride in Patients with Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Belgium Bulgaria Croatia Denmark France Hungary +8
  • Study Comparing Rituximab and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    France
  • Study on the Safety and Effectiveness of Dimethyl Fumarate for Children Aged 10-17 with Relapsing-Remitting Multiple Sclerosis

    Not recruiting

    3 1 1
    Investigated Drugs:
    France